JDRF T1D Fund LLC 3
3 · Pandion Therapeutics, Inc. · Filed Jul 16, 2020
Insider Transaction Report
Form 3
JDRF T1D Fund LLC
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (222,020 underlying)Series A Prime Preferred Stock
→ Common Stock (204,313 underlying)
Footnotes (2)
- [F1]The Series A Prime Preferred Stock is convertible into Common Stock on a 4.6410-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]The Series B Preferred Stock is convertible into Common Stock on a 5.0994-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.